Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
Media
L’autogreffe fécale pour restaurer sa flore intestinale.
Date :
Previous Post
Chronique Santé : Essai clinique sur la flore intestinale aux hôpitaux sud de Lyon.
Next Post
MaaT Pharma and BIOASTER enter in collaboration to investigate the potentiality to expand fecal microbiota in vitro
Close Menu
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
MaaT Pharma dans les médias
MaaT Pharma in the News
Devenez membre du club
Become a member of the club
